Globeflex Capital’s Quest Diagnostics DGX Stock Holding History

Globeflex Capital’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-2,049	Closed	-$283K	–	489
2023 Q4	$283K	Hold	2,049	–	–	0.03%	309
2023 Q3	$250K	Hold	2,049	–	–	0.03%	304
2023 Q2	$288K	Sell	2,049 -485	-19%	-$66.9K	0.03%	297
2023 Q1	$359K	Hold	2,534	–	–	0.04%	285
2022 Q4	$396K	Hold	2,534	–	–	0.05%	279
2022 Q3	$311K	Buy	2,534 +1,137	+81%	+$150K	0.05%	308
2022 Q2	$186K	Hold	1,397	–	–	0.05%	326
2022 Q1	$191K	Hold	1,397	–	–	0.04%	344
2021 Q4	$242K	Hold	1,397	–	–	0.05%	341
2021 Q3	$203K	Hold	1,397	–	–	0.04%	330
2021 Q2	$184K	Buy	1,397 +319	+30%	+$41.8K	0.03%	378
2021 Q1	$138K	Hold	1,078	–	–	0.03%	397
2020 Q4	$128K	Hold	1,078	–	–	0.03%	405
2020 Q3	$123K	Buy	+1,078	New	+$127K	0.03%	391
2015 Q3	–	Sell	-4,776	Closed	-$346K	–	518
2015 Q2	$346K	Buy	4,776 +80	+2%	+$5.91K	0.06%	336
2015 Q1	$361K	Buy	+4,696	New	+$336K	0.07%	309

Other funds holding DGX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

DSA

Davis Selected Advisers Tucson, Arizona $23.3B AUM 26.95% 1-Year Est. Return

Grantham, Mayo, Van Otterloo & Co (GMO) Boston, Massachusetts $44.4B AUM 36.05% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Globeflex Capital's DGX Position: Q1 2024 in Review

Globeflex Capital sold out of Quest Diagnostics (DGX) in Q1 2024, closing a stake of 2,049 shares — an estimated $283K sold.

Globeflex Capital first reported a position in DGX in Q1 2015 and held it in 16 quarters. The position peaked at $396K in Q4 2022. 819 funds tracked by Wall St. Rank hold DGX as of Q1 2024.

Globeflex Capital reported no remaining Quest Diagnostics position as of Q1 2024 after selling out during the quarter.
Globeflex Capital sold 2,049 Quest Diagnostics shares in Q1 2024, an estimated $283K.
Globeflex Capital first reported a position in Quest Diagnostics in Q1 2015 and held it in 16 quarters.
Globeflex Capital's Quest Diagnostics position peaked at $396K in Q4 2022.
819 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2024.

Based on Globeflex Capital's 13F filing for Q1 2024, filed 14 May 2024.